Literature DB >> 1354274

Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. The Research Group on Instability in Coronary Artery Disease in Southeast Sweden.

I Nyman1, H Larsson, L Wallentin.   

Abstract

On exercise testing after an episode of unstable coronary artery disease (CAD; unstable angina or non-Q-wave myocardial infarction), a proportion of patients show ST-segment depression, indicating myocardial ischaemia, but do not report concomitant symptoms of angina. Treatment of such "silent" ischaemia aims mainly to reduce the risk of subsequent cardiac events. We have studied the effect of low-dose aspirin in patients with myocardial ischaemia defined at the predischarge test as silent (though patients might have had symptomatic ischaemia at other times) or symptomatic. 740 men with unstable CAD aged 70 years or less underwent symptom-limited exercise testing before hospital discharge; 144 showed ST depression without pain and 230 ST depression with simultaneous chest pain. Of the silent ischaemia group, 67 were randomly assigned placebo and 77 aspirin (75 mg daily); the corresponding numbers in the symptomatic group were 125 and 105. Angina symptoms were less common in the silent than in the symptomatic ischaemia group both before inclusion and during follow-up, and a greater proportion of the silent ischaemia group were included because of myocardial infarction. In both ischaemia groups aspirin treatment reduced the risk of subsequent myocardial infarction or death by 3 months' follow-up (silent 4% of aspirin-treated vs 21% of placebo-treated patients, p = 0.004; symptomatic 9% vs 18%, p = 0.05); at 12 months' follow-up a significant benefit of aspirin was still apparent in the silent ischaemia group (9% vs 28%, p = 0.005) but not in the symptomatic group (13% vs 22%, p = 0.109). Low-dose aspirin reduced the risk of subsequent myocardial infarction at least as well in silent as in symptomatic myocardial ischaemia. Since improvement of outlook is the main treatment objective in symptom-free patients, aspirin should be a mainstay of their treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1354274     DOI: 10.1016/0140-6736(92)91706-e

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

Review 1.  North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.

Authors:  M Eccles; N Freemantle; J Mason
Journal:  BMJ       Date:  1998-04-25

2.  Number needed to treat is a simple measure of treatment efficacy for clinicians.

Authors:  S V Rajkumar; P Sampathkumar; A B Gustafson
Journal:  J Gen Intern Med       Date:  1996-06       Impact factor: 5.128

3.  The case for preoperative aspirin administration in patients undergoing elective CABG: is it open or closed?

Authors:  Regina Kayse; Richard C Becker
Journal:  Ann Transl Med       Date:  2016-10

Review 4.  Silent myocardial ischemia: recent developments.

Authors:  Peter F Cohn
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

5.  Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding.

Authors:  C M Wilcox; L N Alexander; G A Cotsonis; W S Clark
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

Review 6.  Daily life cardiac ischaemia. Should it be treated?

Authors:  B D Bertolet; C J Pepine
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 7.  Antiplatelet therapy--Part I.

Authors:  S H Goodnight; B M Coull; J H McAnulty; L M Taylor
Journal:  West J Med       Date:  1993-04

8.  Sudden cardiac death and the potential role of beta adrenoceptor-blocking drugs.

Authors:  O M Jolobe
Journal:  Postgrad Med J       Date:  1994-07       Impact factor: 2.401

9.  Gastro-duodenal injury associated with intake of 100-325mg aspirin daily.

Authors:  O M Jolobe; N S Price
Journal:  Postgrad Med J       Date:  1994-06       Impact factor: 2.401

10.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.